...
首页> 外文期刊>ESC Heart Failure >Outcome comparison of mitral valve surgery and MitraClip therapy in patients with severely reduced left ventricular dysfunction
【24h】

Outcome comparison of mitral valve surgery and MitraClip therapy in patients with severely reduced left ventricular dysfunction

机译:二尖瓣手术和Mitroaclip治疗患者患者的结果比较严重降低左心室功能障碍

获取原文
           

摘要

Aims The aim of this study was to compare the outcomes of surgical mitral valve repair or replacement (sMVR) and percutaneous edge‐to‐edge repair using MitraClip (pMVR) in patients with severe left ventricular dysfunction affected by functional mitral regurgitation (FMR). Methods and results We retrospectively identified 132 patients with left ventricular ejection fraction (LVEF)?≦?30% submitted to sMVR (n?=?47) or pMVR (n?=?85) for FMR at our centre from January 2013 to December 2017. To adjust for baseline imbalances, we used a propensity score matching by age, logistic EuroSCORE, and left ventricular end‐systolic volume. After being matched, MitraClip therapy showed lower perioperative mortality and rate of complications yet increased residual mitral regurgitation (MR) grade than did surgery (0.2?±?0.50 in sMVR vs. 1.3?±?0.88 in pMVR, P??0.0001). According to stratified multivariate Cox model analysis, residual MR severity was an independent risk factor for cardiac death [hazard ratio (HR), 2.81; 95% confidence interval [CI], 1.44–5.48, P?=?0.0025] and re‐hospitalization for heart failure (HR, 3.07; 95% CI, 1.50–6.29, P?=?0.0022) at 1?year follow‐up. Stratified multivariable Cox regression analysis at 3?years identified pMVR as risk factor for cardiac death (HR, 0.19; 95% CI, 0.040–0.86, P?=?0.031) and re‐hospitalization for heart failure (HR, 0.28; 95% CI, 0.077–0.99, P?=?0.048). Conclusions In patients with FMR and LVEF?≤?30%, MitraClip therapy resulted in lower perioperative complications and mortality than sMVR. However, surgically treated patients who survived the perioperative stage had less residual MR and experienced lower rates of re‐hospitalization for heart failure at 1?year and lower cardiac mortality at 1 and 3?years of follow‐up than did patients undergoing pMVR.
机译:旨在将本研究的目的进行了使用含有二尖瓣流反流(FMR)影响的严重左心室功能障碍患者的患者的外科二尖瓣修复或更换(SMVR)和经皮边缘到边缘修复的结果。方法和结果我们回顾性鉴定了132例左心室喷射部分(LVEF)的患者(LVEF)?≤30%,从2013年1月到12月,向SMVR(n?= 37)或PMVR(n?= 385岁)提交给FMR 2017年。为了调整基线不平衡,我们使用年龄,后勤欧摩车和左心室最终收缩量匹配的倾向得分。在匹配后,Mitraclip治疗显示围手术期降低,并发症率较低,并且残留二尖瓣流动(MR)等级比手术(0.2?±0.50在SMVR与1.3中的0.88中,P?<0.000) 。根据分层多元COX模型分析,残留的MR严重程度是心脏死亡的独立危险因素[危险比(HR),2.81; 95%置信区间[CI],1.44-5.48,p?= 0.0025]并重新住院治疗心力衰竭(HR,3.07; 95%CI,1.50-6.29,p?= 0.0022),在关注 - 向上。三年的分层多变量Cox回归分析确定了PMVR作为心脏死亡的危险因素(HR,0.19; 95%CI,0.040-0.86,P?= 0.031),并重新住院治疗心力衰竭(HR,0.28; 95% CI,0.077-0.99,p?= 0.048)。结论FMR和LVEF患者≤α≤30%,MITRACLIP治疗导致围手术期并发症低于SMVR。然而,手术治疗围手术期潜水的患者在1年和3年龄在1和3年后的心力衰竭的心力衰竭较低的重新住院率较低,并且在1年和3年后的后续患者比接受PMVR的患者的后续患者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号